Holger Eidtmann

23.8k total citations · 2 hit papers
123 papers, 8.7k citations indexed

About

Holger Eidtmann is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Holger Eidtmann has authored 123 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Oncology, 78 papers in Cancer Research and 42 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Holger Eidtmann's work include Breast Cancer Treatment Studies (69 papers), Cancer Treatment and Pharmacology (55 papers) and HER2/EGFR in Cancer Research (48 papers). Holger Eidtmann is often cited by papers focused on Breast Cancer Treatment Studies (69 papers), Cancer Treatment and Pharmacology (55 papers) and HER2/EGFR in Cancer Research (48 papers). Holger Eidtmann collaborates with scholars based in Germany, United States and Belgium. Holger Eidtmann's co-authors include Gϋnter von Minckwitz, J. Hilfrich, Christian Jackisch, Sibylle Loibl, Jens‐Uwe Blohmer, Jens Huober, Serban Dan Costa, Manfred Kaufmann, Michael Untch and Bernd Gerber and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Holger Eidtmann

120 papers receiving 8.5k citations

Hit Papers

Definition and Impact of ... 2012 2026 2016 2021 2012 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
    2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →
  2. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
    2015 432 citations Carsten Denkert, Paolo Nucíforo et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Holger Eidtmann 6.6k 5.1k 1.7k 1.7k 1.3k 123 8.7k
Serban Dan Costa 4.8k 0.7× 4.2k 0.8× 1.3k 0.8× 1.7k 1.0× 978 0.7× 103 7.6k
Peter Dubsky 3.3k 0.5× 2.7k 0.5× 1.2k 0.7× 779 0.5× 1.2k 0.9× 153 6.0k
Priya Rastogi 4.8k 0.7× 3.5k 0.7× 1.2k 0.7× 990 0.6× 1.4k 1.0× 142 6.7k
Mikhail Lichinitser 7.8k 1.2× 2.0k 0.4× 1.3k 0.8× 720 0.4× 3.8k 2.9× 62 9.9k
M. Tubiana-Hulin 3.3k 0.5× 1.7k 0.3× 879 0.5× 587 0.3× 875 0.7× 60 4.6k
Lina Asmar 3.9k 0.6× 2.1k 0.4× 505 0.3× 1.2k 0.7× 2.7k 2.0× 169 6.4k
Gilles Romieu 4.8k 0.7× 1.9k 0.4× 873 0.5× 382 0.2× 2.1k 1.6× 136 6.2k
Mauro G. Mastropasqua 2.5k 0.4× 2.9k 0.6× 430 0.3× 1.3k 0.8× 898 0.7× 96 4.6k
Roberto Hegg 6.6k 1.0× 2.4k 0.5× 1.6k 0.9× 408 0.2× 2.3k 1.7× 87 8.3k
Brigitte Sigal‐Zafrani 2.3k 0.3× 2.2k 0.4× 680 0.4× 1.1k 0.7× 541 0.4× 110 4.5k

Countries citing papers authored by Holger Eidtmann

Since Specialization
Citations

This map shows the geographic impact of Holger Eidtmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger Eidtmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger Eidtmann more than expected).

Fields of papers citing papers by Holger Eidtmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger Eidtmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger Eidtmann. The network helps show where Holger Eidtmann may publish in the future.

Co-authorship network of co-authors of Holger Eidtmann

This figure shows the co-authorship network connecting the top 25 collaborators of Holger Eidtmann. A scholar is included among the top collaborators of Holger Eidtmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger Eidtmann. Holger Eidtmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loibl, Sibylle, Silvia Darb‐Esfahani, Jens Huober, et al.. (2016). Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research. 22(11). 2675–2683. 34 indexed citations
2.
Shi, Wenhao, Tingting Jiang, Paolo Nucíforo, et al.. (2016). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals of Oncology. 28(1). 128–135. 51 indexed citations
3.
4.
Darb‐Esfahani, Silvia, Gϋnter von Minckwitz, Carsten Denkert, et al.. (2014). Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 14(1). 546–546. 67 indexed citations
5.
Minckwitz, Gϋnter von, Jens‐Uwe Blohmer, Serban Dan Costa, et al.. (2013). Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology. 31(29). 3623–3630. 265 indexed citations
6.
Criscitiello, Carmen, Hatem A. Azim, Dominique Agbor‐Tarh, et al.. (2013). Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Annals of Oncology. 24(8). 1980–1985. 26 indexed citations
7.
Gebhart, Géraldine, Cristina Gámez‐Cenzano, Eileen Holmes, et al.. (2013). 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. Journal of Nuclear Medicine. 54(11). 1862–1868. 104 indexed citations
8.
Azim, Hatem A., Dominique Agbor‐Tarh, Ian Bradbury, et al.. (2013). Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. Journal of Clinical Oncology. 31(36). 4504–4511. 45 indexed citations
9.
Minckwitz, Gϋnter von, Mahdi Rezai, Peter A. Fasching, et al.. (2013). Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro). Annals of Oncology. 25(1). 81–89. 51 indexed citations
10.
Sinn, Bruno V., Gϋnter von Minckwitz, Carsten Denkert, et al.. (2013). Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Annals of Oncology. 24(9). 2316–2324. 30 indexed citations
11.
Gerber, B., Sibylle Loibl, Holger Eidtmann, et al.. (2013). Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Annals of Oncology. 24(12). 2978–2984. 105 indexed citations
12.
Sinn, Bruno V., Gϋnter von Minckwitz, Carsten Denkert, et al.. (2012). 8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Oncology. 23. ii17–ii17.
13.
Minckwitz, Gϋnter von, Silvia Darb‐Esfahani, Sibylle Loibl, et al.. (2011). Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40). Breast Cancer Research and Treatment. 132(3). 863–870. 35 indexed citations
14.
Clemens, Michael, Holger Eidtmann, Ulrike Nitz, et al.. (2010). Trastuzumab Single-Drug Therapy after Failure of Cytotoxic Treatment for Metastatic Breast Cancer. Onkologie. 33(8-9). 425–430. 4 indexed citations
15.
Riethdorf, Sabine, Volkmar Müller, Liling Zhang, et al.. (2010). Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clinical Cancer Research. 16(9). 2634–2645. 398 indexed citations
16.
Eidtmann, Holger, Richard de Boer, Nigel Bundred, et al.. (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Annals of Oncology. 21(11). 2188–2194. 229 indexed citations
17.
Reimer, Toralf, Jochem Potenberg, Bettina Conrad, et al.. (2009). 0155 ICE study: Ibandronate with or without capecitabine in elderly patients with early breast cancer. The Breast. 18. S58–S58. 2 indexed citations
18.
19.
Untch, Michael, Steffen Kahlert, Holger Eidtmann, et al.. (2004). Anthracycline and trastuzumab in breast cancer treatment.. PubMed. 18(14 Suppl 14). 59–64. 6 indexed citations
20.
Minckwitz, Gϋnter von, Jens‐Uwe Blohmer, Günther Raab, et al.. (2004). In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Annals of Oncology. 16(1). 56–63. 146 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Serban Dan Costa Breakdown of academic impact, for papers by Peter Dubsky Breakdown of academic impact, for papers by Priya Rastogi Breakdown of academic impact, for papers by Mikhail Lichinitser Breakdown of academic impact, for papers by M. Tubiana-Hulin Breakdown of academic impact, for papers by Lina Asmar Breakdown of academic impact, for papers by Gilles Romieu Breakdown of academic impact, for papers by Mauro G. Mastropasqua Breakdown of academic impact, for papers by Roberto Hegg Breakdown of academic impact, for papers by Brigitte Sigal‐Zafrani
Rankless by CCL
2026